DK1331938T3 - Anvendelse af en stamme af Lactobacillus til reduktion af risikofaktorer forbundet med det metaboliske syndrom - Google Patents

Anvendelse af en stamme af Lactobacillus til reduktion af risikofaktorer forbundet med det metaboliske syndrom

Info

Publication number: DK1331938T3
Authority: DK; Denmark
Prior art keywords: lactobacillus; strain; metabolic syndrome; risk factors; factors associated
Prior art date: 2000-11-10

Application number

DK01983031T

Other languages

Danish (da)

English (en)

Inventor

Marie-Louise Johansson

Marek Naruszewicz

Original Assignee

Probi Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-10

Filing date

2001-11-12

Publication date

2007-02-12

2001-11-12 Application filed by Probi Ab filed Critical Probi Ab

2007-02-12 Application granted granted Critical

2007-02-12 Publication of DK1331938T3 publication Critical patent/DK1331938T3/da

Links

241000186660 Lactobacillus Species 0.000 title abstract 2
208000001145 Metabolic Syndrome Diseases 0.000 title abstract 2
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title abstract 2
229940039696 lactobacillus Drugs 0.000 title abstract 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
240000006024 Lactobacillus plantarum Species 0.000 abstract 2
235000013965 Lactobacillus plantarum Nutrition 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
229940072205 lactobacillus plantarum Drugs 0.000 abstract 2
206010020772 Hypertension Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
102000007330 LDL Lipoproteins Human genes 0.000 abstract 1
108010007622 LDL Lipoproteins Proteins 0.000 abstract 1
102000016267 Leptin Human genes 0.000 abstract 1
108010092277 Leptin Proteins 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
210000001072 colon Anatomy 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
229940039781 leptin Drugs 0.000 abstract 1
235000019260 propionic acid Nutrition 0.000 abstract 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Plant Substances (AREA)

DK01983031T 2000-11-10 2001-11-12 Anvendelse af en stamme af Lactobacillus til reduktion af risikofaktorer forbundet med det metaboliske syndrom DK1331938T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0004124A SE0004124D0 (sv)	2000-11-10	2000-11-10	New use
PCT/SE2001/002500 WO2002038165A1 (fr)	2000-11-10	2001-11-12	Utilisation d'une souche de lactobacillus reduisant les facteurs de risque associes au syndrome metabolique

Publications (1)

Publication Number	Publication Date
DK1331938T3 true DK1331938T3 (da)	2007-02-12

Family

ID=20281779

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01983031T DK1331938T3 (da)	2000-11-10	2001-11-12	Anvendelse af en stamme af Lactobacillus til reduktion af risikofaktorer forbundet med det metaboliske syndrom

Country Status (16)

Country	Link
US (1)	US20040048356A1 (fr)
EP (1)	EP1331938B1 (fr)
JP (1)	JP4200518B2 (fr)
KR (2)	KR100886728B1 (fr)
CN (1)	CN1226039C (fr)
AT (1)	ATE343392T1 (fr)
AU (2)	AU2002214486B2 (fr)
CA (1)	CA2434035C (fr)
DE (1)	DE60124131T2 (fr)
DK (1)	DK1331938T3 (fr)
ES (1)	ES2269480T3 (fr)
NO (1)	NO330992B1 (fr)
NZ (1)	NZ525657A (fr)
PL (1)	PL203824B1 (fr)
SE (1)	SE0004124D0 (fr)
WO (1)	WO2002038165A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002526413A (ja) *	1998-10-01	2002-08-20	プロビエービー	酸化性ストレス因子の減少
CN1293185C (zh) *	2002-10-30	2007-01-03	食品工业发展研究所	具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
CN1237168C (zh) *	2002-10-30	2006-01-18	食品工业发展研究所	具有降低与同化胆固醇能力的耐酸与耐胆盐乳杆菌分离株
CN1293186C (zh) *	2002-10-30	2007-01-03	食品工业发展研究所	具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
CN1293187C (zh) *	2002-10-30	2007-01-03	食品工业发展研究所	具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
SE527555C2 (sv)	2003-04-04	2006-04-11	Probi Ab	Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
JP5363811B2 (ja)	2005-09-28	2013-12-11	ノルディスクリバランスアクティーゼルスカブ	治療エフェクターとしてプロバイオティック細菌と発酵穀物を用いるｉｂｄ及びｉｂｓの治療
RU2008134892A (ru)	2006-01-27	2010-03-10	Даниско А/С (Dk)	Применение пробиотичеких микроорганизмов для лечения и профилактики ожирения и связанных с ним расстройств
JP5229977B2 (ja) *	2006-09-08	2013-07-03	雪印メグミルク株式会社	血中アディポネクチン濃度増加促進及び／又は減少抑制剤
JP5201832B2 (ja) *	2006-12-25	2013-06-05	花王株式会社	脂肪分解促進用皮膚外用剤
JP2008214253A (ja)	2007-03-02	2008-09-18	Snow Brand Milk Prod Co Ltd	内臓脂肪減少剤
SE532899C2 (sv)	2007-06-08	2010-05-04	Probi Ab	Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel
EP2011506A1 (fr) *	2007-07-05	2009-01-07	Nestec S.A.	Supplémentation de régime maternel
KR101010914B1 (ko) *	2008-04-28	2011-01-26	주식회사 엔유씨전자	항비만 및 뇌기능개선 관련 생리활성 기능을 가지는 프로바이오틱 유산균 락토바실러스 플란타늄
CN102448477A (zh)	2009-03-25	2012-05-09	科·汉森有限公司	益生菌在调节体重中的用途
WO2010146568A2 (fr)	2009-06-19	2010-12-23	Danisco A/S	Bifidobactéries pour le traitement du diabète et d'affections apparentées
CA2784723C (fr)	2009-12-22	2021-01-12	Probi Ab	Compositions non fermentees comprenant une fraction a base de cereales et un probiotique et des utilisations de celles-ci
KR101426276B1 (ko) *	2012-08-16	2014-08-05	주식회사한국야쿠르트	심장질환 및 뇌졸중을 유발하는 거품세포 형성 억제 및 혈관 병변 형성을 억제하는 활성을 가지는 락토바실러스 플란타룸 ｈｙ７７１２를 유효성분으로 함유하는 제품
KR101470995B1 (ko) *	2013-08-30	2014-12-09	주식회사 바이오리쏘스	프로피온산 생산능을 갖는 미생물 및 그를 포함하는 조사료 조성물
KR101500974B1 (ko) *	2014-08-22	2015-03-13	(주) 에이투젠	항염증 및 대사성질환 개선 효능을 가지는 락토바실러스 플란타룸 hac01 균주 및 이의 용도
CN105105145B (zh) *	2015-09-14	2022-04-22	吉林省命之元生物科技有限公司	一株植物乳杆菌及其在制备降血糖血脂的功能性食品中的应用
GB201519327D0 (en)	2015-11-02	2015-12-16	Optibiotix Health Ltd	Composition
CN105567601A (zh) *	2016-01-29	2016-05-11	江苏绿科生物技术有限公司	一种植物乳杆菌及其应用
WO2018145294A1 (fr)	2017-02-10	2018-08-16	Perfect (China) Co., Ltd.	Nouvelles souches de bifidobactéries probiotiques
WO2018216735A1 (fr) *	2017-05-26	2018-11-29	ハウスウェルネスフーズ株式会社	Composition pour la prévention, la régression ou le traitement du syndrome métabolique
KR102063772B1 (ko) *	2019-07-23	2020-01-08	주식회사 메디오젠	혈당 강하 효과 및 항산화 효과를 갖는 유산균
WO2022000077A1 (fr) *	2020-07-01	2022-01-06	Panag Pharma Inc.	Résidu de plant de cannabis et son utilisation
CN112126604B (zh) *	2020-09-30	2022-05-17	江南大学	一株可降低高血压发生风险因子的植物乳杆菌及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9501056D0 (sv) *	1995-03-23	1995-03-23	Probi Ab	Epithelial adherent lactobacilli
SE510753C2 (sv) *	1997-08-05	1999-06-21	Probi Ab	Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
US6589969B1 (en) *	1998-10-16	2003-07-08	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient

2000
- 2000-11-10 SE SE0004124A patent/SE0004124D0/xx unknown
2001
- 2001-11-12 EP EP01983031A patent/EP1331938B1/fr not_active Expired - Lifetime
- 2001-11-12 DK DK01983031T patent/DK1331938T3/da active
- 2001-11-12 WO PCT/SE2001/002500 patent/WO2002038165A1/fr not_active Ceased
- 2001-11-12 AU AU2002214486A patent/AU2002214486B2/en not_active Expired
- 2001-11-12 CN CNB018218849A patent/CN1226039C/zh not_active Expired - Lifetime
- 2001-11-12 KR KR1020037006309A patent/KR100886728B1/ko not_active Expired - Lifetime
- 2001-11-12 CA CA2434035A patent/CA2434035C/fr not_active Expired - Lifetime
- 2001-11-12 ES ES01983031T patent/ES2269480T3/es not_active Expired - Lifetime
- 2001-11-12 US US10/416,184 patent/US20040048356A1/en not_active Abandoned
- 2001-11-12 KR KR1020087011377A patent/KR20080047628A/ko not_active Ceased
- 2001-11-12 NZ NZ525657A patent/NZ525657A/en not_active IP Right Cessation
- 2001-11-12 PL PL362221A patent/PL203824B1/pl unknown
- 2001-11-12 AU AU1448602A patent/AU1448602A/xx active Pending
- 2001-11-12 AT AT01983031T patent/ATE343392T1/de active
- 2001-11-12 DE DE60124131T patent/DE60124131T2/de not_active Expired - Lifetime
- 2001-11-12 JP JP2002540747A patent/JP4200518B2/ja not_active Expired - Fee Related
2003
- 2003-05-08 NO NO20032056A patent/NO330992B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU1448602A (en)	2002-05-21
CA2434035A1 (fr)	2002-05-16
JP2004520276A (ja)	2004-07-08
NO20032056D0 (no)	2003-05-08
CA2434035C (fr)	2011-06-07
PL203824B1 (pl)	2009-11-30
ES2269480T3 (es)	2007-04-01
JP4200518B2 (ja)	2008-12-24
NZ525657A (en)	2005-05-27
AU2002214486B2 (en)	2007-04-26
DE60124131T2 (de)	2007-03-29
EP1331938A1 (fr)	2003-08-06
DE60124131D1 (de)	2006-12-07
KR20040018304A (ko)	2004-03-03
CN1486189A (zh)	2004-03-31
NO330992B1 (no)	2011-09-05
CN1226039C (zh)	2005-11-09
EP1331938B1 (fr)	2006-10-25
US20040048356A1 (en)	2004-03-11
SE0004124D0 (sv)	2000-11-10
WO2002038165A1 (fr)	2002-05-16
NO20032056L (no)	2003-05-08
PL362221A1 (en)	2004-10-18
ATE343392T1 (de)	2006-11-15
KR20080047628A (ko)	2008-05-29
KR100886728B1 (ko)	2009-03-04

Publication	Publication Date	Title
DK1331938T3 (da)	2007-02-12	Anvendelse af en stamme af Lactobacillus til reduktion af risikofaktorer forbundet med det metaboliske syndrom
IL161154A0 (en)	2004-08-31	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP2175834B8 (fr)	2012-08-22	Formulation de protéine de fusion glp-1-fc
NO20053537L (no)	2005-08-26	Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
NZ594814A (en)	2013-03-28	Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
NO20064388L (no)	2006-11-28	Kaseinavledede peptider og terapeutiske anvendelser derav
GB0213612D0 (en)	2002-07-24	Organic compounds
BR9811825A (pt)	2000-08-15	Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DE60111570D1 (de)	2005-07-21	Isoindolin-1-on als glukokinaseaktivatoren
WO2006074330A3 (fr)	2007-01-25	Inhibiteurs de l'enzyme 11-beta-hydroxysteroide dehydrogenase de type 1
WO2007061661A3 (fr)	2008-12-11	Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1
WO2002083879A3 (fr)	2002-12-12	Immunotherapie basee sur des cellules dendritiques
WO2011031063A3 (fr)	2011-08-11	Composition de prévention ou de traitement de troubles métaboliques contenant l'anticorps anti-4-1bb
AU2002338852A1 (en)	2003-04-22	Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2002044113A3 (fr)	2002-09-12	Utilisation de derives d'acide acetique(-)(3-halomethylphenoxy)(4-halophenyl) dans le traitement de la resistance a l'insuline, le diabete de type 2, l'hyperlipidemie et l'hyperuricemie
NO20074062L (no)	2007-11-13	Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn
Friedmann	2006	Escherich and escherichia
CL2000002938A1 (es)	2009-05-15	Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benciloxiimino]-4-fenilbutirico, composicion farmaceutica que los comprende y su uso en el tratamiento o prevencion de la diabetes mellitus, hiperlipemia, disminucion en la tolerancia a la glucosa, enfermedades inflamatorias, arteriosclerosis.
EP1421945A4 (fr)	2005-06-22	Absorbant/adsorbant d'acide biliaire
WO2003087325A3 (fr)	2004-04-15	Methodes et compositions de prevention et de traitement d'infections microbiennes
WO2004009029A3 (fr)	2007-08-16	Compositions et procedes de traitement et de prevention d'infections
WO2006004696A3 (fr)	2006-10-26	Compositions et methodes pour la prevention et la regulation de l'hypoglycemie induite par l'insuline
WO2005097153A3 (fr)	2005-12-15	Extraits de fruit de la passion et utilisations de ces extraits
WO2003032965A3 (fr)	2003-11-27	Methode de reduction du diabete de type 2 chez des patients a haut risque
AR034374A1 (es)	2004-02-18	Combinacion de un inhibidor de ptpasa y un inhibidor de ace